Trial Profile
A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 16 Nov 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 11 Nov 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 26 Apr 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 12 May 2021 Planned End Date changed from 30 Jun 2021 to 1 Dec 2022.